Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APT Pharmaceuticals, a specialty drug development company which provides inhaled treatments for serious lung diseases, has appointed Stephen Aselage to its board of directors.
Subscribe to our email newsletter
Mr Aselage is currently senior vice president of global commercial development at BioMarin Pharmaceuticals. Prior to joining BioMarin, he held the position of executive vice president of global commercial operations at Cell Therapeutics.
Prior to Cell Therapeutics, Mr Aselage served as senior vice president of North American sales and marketing for Sangstat. He has also held a variety of other positions at biotechnology and pharmaceutical companies, including Advanced Tissue Sciences, Rhone-Poulenc Rorer Pharmaceuticals, Genentech and Bristol Laboratories.
Stephen Dilly, president and CEO of APT Pharmaceuticals, said: “Steve brings decades of experience in the commercialization of new products in the biopharmaceutical industry. We now have a board with deep experience in all critical functional areas to support our team as we successfully develop and launch products for serious lung diseases.”